| Name | Title | Contact Details |
|---|---|---|
Yuhong Qiu |
VP, Regulatory Affairs | Profile |
Jim Pepin |
General Counsel | Profile |
Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance their therapeutic effectiveness against a broad range of diseases that conventional medicines do not readily address.
Hohenstein Institute America, Inc is a Elon, NC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
MediGene, Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
BioE is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
GTC Biotherapeutics is a Framingham, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.